Episode Details

Cancer recurrence often stems from dormant cancer cells, not just the primary tumor. These "sleeper cells" can reawaken years later, leading to metastasis.

This video presents a smarter approach to cancer treatment, focusing on preventing recurrence after remission using off-label drugs and integrative agents.

🎯 What You’ll Learn in This Episode:
- Why cancer recurrence often begins with dormant cells
- What micrometastatic disease means
- How mTOR fuels cancer regrowth
- How autophagy helps cancer survive under stress
- The role of off-label repurposed medications
- Natural compounds that influence growth pathways
- Why zinc and vitamin D matter for immune function
- The right questions to ask your doctor after remission

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“Remission is not the end of treatment — it’s the beginning of prevention.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: 

https://www.scirp.org/journal/paperinformation?paperid=132493